76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Zealand Pharma A-S
Closed
476.3 2.32
Overview
Share price change
24h
Min
465.5
Max
481
Income | -44M -335M |
|---|---|
Sales | -964K 8.1M |
EPS | -4.75 |
Profit margin | -4,144.13 |
Employees | 385 |
EBITDA | 8.1M -253M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +25.15% upside |
Next Earnings | 14 Aug 2025 |
|---|
Market Cap | 1.8B 32B |
|---|---|
Previous open | 473.98 |
Previous close | 476.3 |
Zealand Pharma A-S Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Zealand Pharma A-S Forecast
Price Target
By TipRanks
25.15% upside
12 Months Forecast
Average 270.582 DKK 25.15%
High 270.568 DKK
Low 270.568 DKK
Based on 1 Wall Street analysts offering 12 month price targets forZealand Pharma A-S - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Zealand Pharma A-S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
